Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27568558 | 0.92 | KCNA3 (0.41) | KCNA3CNR1CNR2GPR55KDM4E | |
| SCHEMBL18347218 | 0.86 | POLB (0.45) | CNR1CNR2GPR55KDM4EALDH1A1 | |
| SCHEMBL18347228 | 0.85 | MAPK14 (0.49) | KCNA3PLA2G7 | |
| SCHEMBL18347213 | 0.85 | THRB (0.45) | KDM4EALDH1A1PLA2G7 | |
| SCHEMBL18347251 | 0.84 | PTGER3 (0.51) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL18347209 | 0.82 | TSHR (0.40) | ALDH1A1PLA2G7SMN1; SMN2 | |
| SCHEMBL18347225 | 0.82 | KCNA3 (0.47) | KCNA3 | |
| SCHEMBL18347219 | 0.81 | PLA2G7 (0.40) | CNR1CNR2GPR55PLA2G7 | |
| SCHEMBL29565027 | 0.81 | TSHR (0.41) | ALDH1A1PLA2G7SMN1; SMN2 | |
| SCHEMBL18347226 | 0.80 | PLA2G7 (0.37) | PLA2G7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240251654-A1 | ORGANIC ELECTROLUMINESCENT DEVICE | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2024-07-25 | — | — | US | claimed |
| US-20260029401-A1 | METHODS AND SYSTEMS FOR CHARACTERIZING PROTEOFORMS OF SIGNIFICANT PROTEINS OF INTEREST | NAUTILUS SUBSIDIARY INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12370164-B2 | Chlorogenic acid composition for promoting a healthy body weight | Vidya Herbs, Inc. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250206708-A1 | AN OXAZIRIDINE PLATFORM FOR TARGETING FUNCTIONAL ALLOSTERIC METHIONINE SITES | NOVARTIS AG (CH) | 2025-06-26 | — | — | US | disclosed |
| EP-4499617-A1 | AN OXAZIRIDINE PLATFORM FOR TARGETING FUNCTIONAL ALLOSTERIC METHIONINE SITES | Novartis AG (CH) | 2025-02-05 | — | — | EP | disclosed |
| US-20250011734-A1 | DGAT1/2-INDEPENDENT ENZYME SYNTHESIZING STORAGE LIPIDS (DIESL) | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis (NL) | 2025-01-09 | — | — | US | disclosed |
| WO-2024262280-A1 | ANTI-GAP 43 ANTIBODY, METHOD FOR PRODUCING SAME, AND TISSUE ANALYSIS METHOD AND KIT FOR TISSUE ANALYSIS METHOD USING SAME | 国立大学法人新潟大学 | 2024-12-26 | — | — | WO | disclosed |
| US-20240426824-A1 | METHODS RELATING TO TREATMENT OF ACUTE MYELOID LEUKEMIA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-12-26 | — | — | US | disclosed |
| US-20240321457-A1 | SYSTEMS FOR AND METHODS OF TREATMENT SELECTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-09-26 | — | — | US | disclosed |
| EP-4430173-A1 | DGAT1/2-INDEPENDENT ENZYME SYNTHESIZING STORAGE LIPIDS (DIESL) | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis (NL) | 2024-09-18 | — | — | EP | disclosed |
| WO-2023192328-A1 | AN OXAZIRIDINE PLATFORM FOR TARGETING FUNCTIONAL ALLOSTERIC METHIONINE SITES | NOVARTIS AG (CH) | 2023-10-05 | — | — | WO | disclosed |
| CN-116779604-A | Integrated circuit | 三星电子株式会社 | 2023-09-19 | — | — | CN | disclosed |
| US-11752124-B2 | Chlorogenic acid composition for supporting healthy lipid levels | Vidya Herbs, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| CN-109087914-B | Integrated circuit and computer-implemented method of generating a layout for an integrated circuit | 三星电子株式会社 | 2023-06-23 | — | — | CN | disclosed |
| WO-2023085926-A1 | DGAT1/2-INDEPENDENT ENZYME SYNTHESIZING STORAGE LIPIDS (DIESL) | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis (NL) | 2023-05-19 | — | — | WO | disclosed |
| US-11572341-B2 | Biguanide compound and use thereof | IMMUNOMET THERAPEUTICS INC. (US) | 2023-02-07 | — | — | US | disclosed |
| WO-2022221553-A1 | AMARANTHUS EXTRACTS FOR USE IN TREATING OBESITY | BIONEXUS LLC (US) | 2022-10-20 | — | — | WO | disclosed |
| US-20220195533-A1 | ARYL HYDROCARBON RECEPTOR (AHR) ACTIVATION SIGNATURE AND METHODS FOR DETERMINING AHR SIGNALING STATUS | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS (DE) | 2022-06-23 | — | — | US | disclosed |
| WO-2022081923-A2 | SYSTEMS FOR AND METHODS OF TREATMENT SELECTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-21 | — | — | WO | disclosed |
| US-20160376235-A1 | Pyridone FabI Inhibitors and Uses Thereof | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2016-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160376235-A1 | Pyridone FabI Inhibitors and Uses Thereof | PLPBP, PDXK, FBP1 | KCNA3 3748/4885CNR1 2546/4885CNR2 3040/4885 |
| US-20260029401-A1 | METHODS AND SYSTEMS FOR CHARACTERIZING PROTEOFORMS OF SIGNIFICANT PROTEINS OF INTEREST | AKT1, LRRK2, AKT2 | KCNA3 4571/4885CNR1 3382/4885CNR2 2838/4885 |
| US-20250206708-A1 | AN OXAZIRIDINE PLATFORM FOR TARGETING FUNCTIONAL ALLOSTERIC METHIONINE SITES | MARCKS, PTMS, DMPK | KCNA3 3631/4885CNR1 4298/4885CNR2 4441/4885 |
| US-11572341-B2 | Biguanide compound and use thereof | MKI67, GCG, GCKR | KCNA3 2570/4885CNR1 2826/4885CNR2 3041/4885 |
| US-20240251654-A1 | ORGANIC ELECTROLUMINESCENT DEVICE | LEF1, EFNA1, EML4 | KCNA3 563/4885CNR1 3626/4885CNR2 4346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.